Hyperion Therapeutics to Report First Quarter 2014 Financial Results After Market on May 6, 2014
April 30, 2014 09:00 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report first quarter 2014 financial results after market close on Tuesday,...
Hyperion Therapeutics to Broaden Orphan Disease Pipeline With Acquisition of Andromeda Biotech Ltd.
April 24, 2014 03:30 ET
|
Hyperion Therapeutics, Inc.
--DiaPep277®, a First-in-Class Immune Intervention Therapy in
Phase 3 Testing for New Onset Type 1 Diabetes--
--Hyperion to Host Analyst/Investor Teleconference Today at 8:45 a.m. EDT (5:45...
Hyperion Therapeutics to Present at the 13th Annual Needham Healthcare Conference
April 01, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., April 1, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 13th Annual Needham Healthcare Conference on...
Hyperion Therapeutics to Present at the 26th Annual Roth Conference
March 07, 2014 09:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., March 7, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 26th Annual Roth Conference on Tuesday, March...
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
February 27, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $18.6 million and $42.2 million for the fourth quarter and full year 2013,...
Hyperion Therapeutics to Present at the Cowen and Company 34th Annual Healthcare Conference
February 26, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Cowen and Company 34th Annual Healthcare...
Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology
February 25, 2014 09:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of...
Hyperion Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results After Market on February 27, 2014
February 24, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report fourth quarter and full year 2013 financial results after market...
Hyperion Therapeutics to Present at the Leerink Global Healthcare Conference
February 06, 2014 09:15 ET
|
Hyperion Therapeutics, Inc.
BRISBANE, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Leerink Global Healthcare Conference on Thursday,...
Hyperion Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
January 08, 2014 16:05 ET
|
Hyperion Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 32nd Annual J.P. Morgan Healthcare...